Emotion and Attention in Alzheimer's Disease (ATEMMA)

NCT ID: NCT03971994

Last Updated: 2022-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-31

Study Completion Date

2021-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to investigate the existence of emotional attention impairments in Alzheimer's Disease, in correlation with amygdala and attention networks alterations. To this end, functional and structural neuroimaging will be used. A face expression recognition task, along with eyetracking, will be used to assess emotional attention impairments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young adults

Participants aged between 18 and 40 years old.

Group Type ACTIVE_COMPARATOR

Facial expression recognition task

Intervention Type BEHAVIORAL

We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.

Healthy old adults

Participants aged between 65 and 95 years old.

Group Type ACTIVE_COMPARATOR

Facial expression recognition task

Intervention Type BEHAVIORAL

We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.

Patients with Alzheimer's Disease

Participants aged between 65 and 95 years old with a diagnosis of Alzheimer's Disease.

Group Type EXPERIMENTAL

Facial expression recognition task

Intervention Type BEHAVIORAL

We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Facial expression recognition task

We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers :

* Affiliation to social security
* Medical examination before study participation
* No contraindication to MRI
* Informed consent signed
* Young adults older than 18 years and younger than 40 years
* Healthy old adults older than 65 years and younger than 95 years
* Visual acuity allowing normal perception of stimuli or corrected to normal vision
* Patients with Alzheimer's Disease :

* Affiliation to social security
* Medical examination before study participation
* No contraindication to MRI
* Informed consent signed
* Patients with Alzheimer's Disease at mild or moderate stage (National Institute on Aging and Alzheimer's Association criteria), diagnosed at Grenoble CMRR (Centre Mémoire de Ressources et de Recherche)
* Patients older than 65 years and younger than 95 years
* MMSE (Mini-Mental State Examination) \> 18/30
* Ability to understand study instructions and give an informed consent
* Visual acuity allowing normal perception of stimuli or corrected to normal vision

Exclusion Criteria

* Every participant having a vascular stent implanted less than 6 weeks before study
* Every participant having a biomedical material implanted that is considered "unsafe" in the list: http://www.mrisafety.com/TheList\_search.asp
* Every acquisition procedure not respecting required conditions by the "conditional" usage in a participant having a biomedical material implanted that is considered "conditional" in the list: http://www.mrisafety.com/TheList\_search.asp
* Every subject having a biomedical material such as a cardiac, neuronal or sensorial stimulator (cochlear implant because of demagnetization, electrode heating or artefact risk) or a ventricular drain without trained medical or paramedical support during MRI for these participants
* Ferromagnetic object inside the eye or the skull, close to nervous structures (displacement and complications risk such as eye or brain damage)
* Claustrophobia
* Psychiatric (e.g., bipolar disorder) or neurological pathology (e.g., epilepsy, Parkinson's Disease) other than Alzheimer's Disease
* Non cooperating participant
* Severe and uncontrolled affection: cardiac, respiratory, haematological, renal, hepatic, cancerous
* Participation to other research protocols with exclusion period or MRI during the past weel
* Drug therapy likely to modulate brain activity : neuroleptics, lithium, etc...
* Alcohol ingestion before study
* Participants concerned by articles L1125-5 to L1121-8 of CSP (Code de la Santé Publique) (pregnant or nursing women, underage or protected adult, person under administrative or judicial oversight
* Participant receiving more than 4500 euros for his participation to other studies involving human person during the past 12 months before this study
* Participant unable to be contacted in case of emergency
* Inability to understand study instructions or give an informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Grenoble

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Grenoble University Hospital

La Tronche, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-A02945-50

Identifier Type: OTHER

Identifier Source: secondary_id

2018/113

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.